Search for a trial

Eurotransplant Senior DR-compatible Program

Reduce acute rejection rates in the Old-for-Old kidney transplantation program. Less acute rejection in these vulnerable older kidneys inevitable translates in better initial kidney function. Less need for acute rejection treatments with high dose…

The effect of lower body negative pressure on cerebral autoregulation in young and elderly healthy volunteers

The aim of the present study is to investigate cerebral vasoreactivity in response to lower body negative pressure in young and elderly healthy men, as a measure of cerebral autoregulatory responsiveness.

Effect study ACRE

Zie pag. 8 protocol

The best muscletest for Duchenne muscular dystrophy;
Outcome measures for Duchenne muscular dystrophy trials

1. Assessment of sensitivity of several outcome measures in muscle force and function in Duchenne muscular dystrophy2. Assessment of reproducability of different outcome measures3. Assessment of clinical relevance of measured change over time in…

DUET-trial; DoUble j or External stenting during kidney Transplantation? Study-protocol

Therefore, in the DUET-trial we will investigate whether double J stenting is indeed superior to the use of an external stent in reducing the number of urological complications after kidney transplantation, as measured by the number of PCN…

A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared With CyBorD Alone in Newly Diagnosed Systemic AL Amyloidosis

This study has been transitioned to CTIS with ID 2024-511967-26-00 check the CTIS register for the current data. Primary Objective: The primary objective is to evaluate the efficacy of daratumumab plus CyBorD compared with CyBorDalone in the…

CareCN: A phase I/II, open-label, study to evaluate the safety and efficacy of an intravenous injection of GNT0003 (Adeno-associated Viral Vector expressing the UGT1A1 transgene) in patients with severe Crigler-Najjar syndrome requiring phototherapy

This study has been transitioned to CTIS with ID 2023-507007-60-00 check the CTIS register for the current data. Primary objectives:Dose escalation part:- To assess the safety and tolerability of an intravenous single-dose administration of GNT0003…

A prospective, randomised, controlled, open-label, multicentre phase III study to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somatostatin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET).

This study has been transitioned to CTIS with ID 2023-510444-21-00 check the CTIS register for the current data. The primary objective is to demonstrate the efficacy of Peptide Receptor Radionuclide Therapy with 177Lu-edotreotide to prolong…

A prospective, multicenter, phase-II trial of ibrutinib plus venetoclax in physically fit patients with creatinine clearance >= 30 ml/min who have relapsed or refractory chronic lymphocytic leukemia (RR-CLL) with or without TP53 aberrations;HOVON 141 CLL / VIsion Trial of the HOVON and Nordic CLL study groups

This study has been transitioned to CTIS with ID 2023-510557-42-00 check the CTIS register for the current data. The primary objective: - Evaluate efficacy of ibrutinib + venetoclax (VI) in terms of proportion of patients fulfilling the criteria for…

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton*s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma

This study has been transitioned to CTIS with ID 2023-507271-21-00 check the CTIS register for the current data. Analysis Study:To evaluate whether the addition of ibrutinib to rituximab will result in prolongation of progression-free survival (PFS…

A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease

This study has been transitioned to CTIS with ID 2023-506399-28-00 check the CTIS register for the current data. Sub-study 1: The objective of sub-study 1 is to evaluate the efficacy and safety of risankizumab versus placebo as maintenance therapy…

A Phase 3, randomized, open label study of lorlatinib (PF 06463922) monotherapy versus crizotinib monotherapy in the first line treatment of patients with advanced ALK positive non small cell lung cancer

This study has been transitioned to CTIS with ID 2023-509169-19-00 check the CTIS register for the current data. To demonstrate that lorlatinib as a single agent (Arm A) is superior to crizotinib alone (Arm B) in prolonging Progression-Free Survival…

A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab, or with Standard of Care Chemotherapy, versus Standard of Care Chemotherapy in participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer

This study has been transitioned to CTIS with ID 2022-501784-40-00 check the CTIS register for the current data. The study aims to demonstrate that treatment with nivolumab combined with ipilimumab will improve efficacy in cisplatin-ineligible…

A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High-risk Smoldering Multiple Myeloma

This study has been transitioned to CTIS with ID 2023-507143-11-00 check the CTIS register for the current data. Primary objective: To determine whether treatment with daratumumab administered subcutaneously (SC) prolongs progression-free survival (…

A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High-Risk, Node-Positive, Early -Stage, Hormone Receptor-Positive, Human Epidermal Receptor 2-Negative, Breast Cancer

This study has been transitioned to CTIS with ID 2023-509671-17-00 check the CTIS register for the current data. The primary objective is To evaluate the efficacy, in terms of invasive disease-free survival (IDFS), as defined by the STEEP System,…